The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

GUANGZHOU, July 5th, 2024 -- MingMed Biotechnology Co., Ltd today announced that its subsidiary, Claruvis Pharmaceutical, has obtained approval from the Center for Drug Evaluation (CDE) on July 2nd, 2

More

News

The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

The World’s First Clinical Trial on Therapeutic Indication of Recombinant Botulinum Toxin Type A (YY001-002) Receives CDE approval

GUANGZHOU, July 5th, 2024 -- MingMed Biotechnology Co., Ltd today announced that its subsidiary, Cla...

Coming soon